Last reviewed · How we verify
CCK (Kinevac) — Competitive Intelligence Brief
marketed
CCK receptor agonist
CCK-A receptor
Gastroenterology / Diagnostic
Small molecule
Live · refreshed every 30 min
Target snapshot
CCK (Kinevac) (CCK (Kinevac)) — GlaxoSmithKline. CCK (cholecystokinin) is a synthetic peptide hormone that binds to CCK receptors to stimulate gallbladder contraction and pancreatic secretion.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CCK (Kinevac) TARGET | CCK (Kinevac) | GlaxoSmithKline | marketed | CCK receptor agonist | CCK-A receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (CCK receptor agonist class)
- GlaxoSmithKline · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CCK (Kinevac) CI watch — RSS
- CCK (Kinevac) CI watch — Atom
- CCK (Kinevac) CI watch — JSON
- CCK (Kinevac) alone — RSS
- Whole CCK receptor agonist class — RSS
Cite this brief
Drug Landscape (2026). CCK (Kinevac) — Competitive Intelligence Brief. https://druglandscape.com/ci/cck-kinevac. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing